Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health.
作者信息
Ertl Hildegund C J, Currie Sue L, Luber Andrew D
机构信息
The Wistar Institute, Philadelphia, PA, United States.
Virion Therapeutics, LLC, Newark, DE, United States.
出版信息
Front Immunol. 2022 Aug 25;13:985382. doi: 10.3389/fimmu.2022.985382. eCollection 2022.
Abstract
摘要
相似文献
1
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health.限制基于腺病毒载体的新冠疫苗的使用可能危及公众和全球健康。
Front Immunol. 2022 Aug 25;13:985382. doi: 10.3389/fimmu.2022.985382. eCollection 2022.
2
Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.公众对 COVID-19 腺病毒载体疫苗的看法：基于血栓性血小板减少性紫癜综合征（TTS）报告和相关监管行动的横断面研究——在六个欧盟成员国开展。
Vaccine. 2024 Jan 25;42(3):556-563. doi: 10.1016/j.vaccine.2023.12.065. Epub 2024 Jan 4.
3
Adenovirus-Based Vaccines and Thrombosis in Pregnancy: A Systematic Review and Meta-analysis.基于腺病毒的疫苗与妊娠相关血栓：系统评价和荟萃分析。
Clin Infect Dis. 2022 Sep 30;75(7):1179-1186. doi: 10.1093/cid/ciac080.
4
Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.新冠病毒疫苗接种后的炎症和血小板活化 - 疫苗诱导免疫性血小板减少症和血栓形成的可能机制。
Front Immunol. 2021 Nov 23;12:779453. doi: 10.3389/fimmu.2021.779453. eCollection 2021.
5
Use of adenovirus type-5 vector vaccines in COVID-19: potential implications for metabolic health?5型腺病毒载体疫苗在2019冠状病毒病中的应用：对代谢健康的潜在影响？
Minerva Endocrinol (Torino). 2022 Sep;47(3):264-269. doi: 10.23736/S2724-6507.22.03797-6. Epub 2022 May 27.
6
Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review.COVID-19 疫苗诱导的免疫性血栓性血小板减少症伴脑静脉窦血栓形成的临床特征和药物治疗：综述。
JAMA Cardiol. 2021 Dec 1;6(12):1451-1460. doi: 10.1001/jamacardio.2021.3444.
7
mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People.基于 mRNA 和腺病毒的 SARS-CoV-2 疫苗在 HIV 阳性人群中的应用。
Viruses. 2022 Apr 1;14(4):748. doi: 10.3390/v14040748.
8
Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis.基于载体的 COVID-19 疫苗接种后脑静脉窦血栓形成和血栓事件：系统评价和荟萃分析。
Neurology. 2021 Nov 23;97(21):e2136-e2147. doi: 10.1212/WNL.0000000000012896. Epub 2021 Oct 5.
9
Audio Interview: Covid-19 Vaccines and Pregnancy - A Conversation with CDC Director Rochelle Walensky.音频访谈：新冠疫苗与怀孕——与美国疾病控制与预防中心主任罗谢尔·瓦伦斯基的对话
N Engl J Med. 2021 Apr 22;384(16):e73. doi: 10.1056/NEJMe2106836.
10
COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis.COVID-19 疫苗相关血栓形成伴血小板减少综合征（TTS）：系统评价和事后分析。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211048815. doi: 10.1177/10760296211048815.
引用本文的文献
1
Scalable production and purification of engineered ARRDC1-mediated microvesicles in a HEK293 suspension cell system.在HEK293悬浮细胞系统中可扩展生产和纯化工程化ARRDC1介导的微泡。
Sci Rep. 2025 Mar 1;15(1):7299. doi: 10.1038/s41598-025-87674-5.
本文引用的文献
1
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.异源接种灭活疫苗后再接种 mRNA 加强针可诱导针对 SARS-CoV-2 奥密克戎变异株的强烈免疫应答。
Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.
2
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.腺病毒载体疫苗（Ad26.COV2.S）初免后的加强免疫的免疫原性和反应原性。
N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19.
3
Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination.接种AZD1222（ChAdOx1 nCoV-19）疫苗后血栓性血小板减少症（TTS）病例的地理分布。
Lancet Glob Health. 2022 Jan;10(1):e33-e34. doi: 10.1016/S2214-109X(21)00545-3.
4
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.ChAdOx1与CAR和PF4相互作用，对伴有血小板减少的血栓形成综合征有影响。
Sci Adv. 2021 Dec 3;7(49):eabl8213. doi: 10.1126/sciadv.abl8213. Epub 2021 Dec 1.
5
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.接种 BNT162b2 疫苗和加强针后，Delta 变异株 SARS-CoV-2 突破感染的病毒载量。
Nat Med. 2021 Dec;27(12):2108-2110. doi: 10.1038/s41591-021-01575-4. Epub 2021 Nov 2.
6
Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings.韩国 BNT162b2 mRNA COVID-19 疫苗接种后心肌炎引起的猝死：病例报告重点关注组织病理学发现。
J Korean Med Sci. 2021 Oct 18;36(40):e286. doi: 10.3346/jkms.2021.36.e286.
7
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.以色列接种 BNT162b2 mRNA 疫苗后出现心肌炎。
N Engl J Med. 2021 Dec 2;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 6.
8
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.腺病毒载体新冠疫苗诱导的免疫性血栓性血小板减少症的相关认识。
Blood. 2021 Dec 2;138(22):2256-2268. doi: 10.1182/blood.2021013231.
9
Myocarditis after Covid-19 mRNA Vaccination.新冠病毒mRNA疫苗接种后的心肌炎
N Engl J Med. 2021 Sep 30;385(14):1332-1334. doi: 10.1056/NEJMc2109975. Epub 2021 Aug 18.
10
Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.腺病毒载体在体内持续存在并维持活化的CD8+ T细胞：对其作为疫苗使用的启示。
Blood. 2007 Sep 15;110(6):1916-23. doi: 10.1182/blood-2007-02-062117. Epub 2007 May 17.
Zotero 插件